UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland | |
---|---|---|---|---|---|---|---|
All invasive xnmsc | 17.0% | 19.0% | 16.8% | NA | NA | 23.8% | 16.3% |
All xnmsc 0-24 | 10.0% | 11.3% | 9.9% | NA | NA | 15.3% | 8.7% |
All xnmsc 25-59 | 17.5% | 20.6% | 17.2% | NA | NA | 26.6% | 18.0% |
All xnmsc 60-79 | 19.3% | 21.0% | 19.2% | NA | NA | 26.6% | 17.1% |
All xnmsc 80+ | 11.1% | 11.7% | 11.1% | NA | NA | 13.3% | 10.8% |
Haematology | 8.8% | 9.3% | 8.8% | NA | NA | 11.7% | 7.5% |
Head and Neck | 40.3% | 51.9% | 38.6% | NA | NA | 66.6% | 50.4% |
Lower GI | 7.6% | 11.1% | 7.0% | NA | NA | 13.3% | 13.0% |
Upper GI | 14.5% | 17.1% | 13.8% | NA | NA | 12.1% | 25.3% |
HPB | 1.9% | 3.4% | 1.7% | NA | NA | 4.5% | 3.9% |
Trachea, Bronchus & Lung | 25.5% | 26.4% | 25.5% | NA | NA | 31.9% | 21.7% |
Melanoma | 0.9% | 1.4% | 0.9% | NA | NA | 2.0% | 1.2% |
Breast | 35.5% | 38.0% | 35.6% | NA | NA | 50.0% | 28.5% |
Prostate | 19.0% | 21.1% | 17.5% | NA | NA | 6.2% | 39.6% |
Cervix | 8.7% | 7.8% | 8.8% | NA | NA | 6.7% | 7.9% |
Other Female Genitals | 16.0% | 16.3% | 16.4% | NA | NA | 23.4% | 9.3% |
Kidney | 4.9% | 5.2% | 4.9% | NA | NA | 6.5% | 4.2% |
Bladder | 14.0% | 14.3% | 14.2% | NA | NA | 19.7% | 9.1% |
Brain and CNS | 31.6% | 45.2% | 29.3% | NA | NA | 54.7% | 51.5% |
Thyroid & other endocrine glands | 7.6% | 7.7% | 7.7% | NA | NA | 10.3% | 4.9% |
CUP | 10.5% | 11.3% | 10.4% | NA | NA | 12.9% | 10.5% |
Other invasive cancer | 12.5% | 12.3% | 12.6% | NA | NA | 13.5% | 10.7% |
Breast in situ | 29.5% | 33.3% | 29.0% | NA | NA | 38.0% | 32.8% |
Cervix in situ | 0.0% | 0.1% | 0.0% | NA | NA | 0.1% | 0.1% |
Other tumours | 1.0% | 1.5% | 0.9% | NA | NA | 2.9% | 0.7% |
Non-Melanoma Skin Cancer | 1.0% | 1.2% | 1.0% | NA | NA | 1.7% | 0.8% |